araag2/HINT huggingface dataset:
Clinical trial NCT00626639 (phase 1/phase 2, status: completed)
Conditions: mucositis, head and neck cancer
ICD codes: J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: placebo, palifermin, cisplatin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  History of newly diagnosed histologically confirmed squamous cell carcinoma (American
             Joint Committee on Cancer [AJCC] Stage II, III, IVA, or IVB) involving either the oral
             cavity, oropharynx, nasopharynx, hypopharynx, or larynx, post surgical resection (R0,
             R1)

          -  Scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of
             surgery

          -  High-risk subject defined by presence of at least one of the following: R1 resection
             margins; T3 or T4 tumor stage; 3 or more positive lymph node metastases; <3 lymph node
             metastases with extracapsular extension of the disease

          -  Radiation treatment field to receive planned dose of at least 50Gy to areas of the
             oral cavity/oropharynx mucosa that can be visualized

        Exclusion Criteria:

          -  Tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors

          -  Metastatic disease (M1) / Stage IV C

          -  Presence or history of any other primary malignancy

          -  History of pancreatitis

          -  Prior radiotherapy to the site of disease

          -  Prior chemotherapy

          -  Other investigational procedures

          -  Thirty days or less since receiving an investigational product or device in another
             clinical trial. Current enrollment in another clinical trial is not permitted unless
             the sole purpose of the trial is for long-term follow-up/survival data
Clinical trial NCT01145014 (phase 1, status: terminated)
Conditions: pain, healthy
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, Z76.3, Z76.2
Drugs: bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria

          1. Healthy male based upon a complete medical history, including the physical
             examination, regarding vital signs (BP, PR), 12 lead ECG measurement, and clinical
             laboratory tests. There is no finding deviating from normal and of clinical relevance.
             There is no evidence of a clinically relevant concomitant disease.

          2. Age 21 and 50 years

          3. BMI 18.5 and <30 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion criteria

          1. Any finding of the medical examination (including BP, PR, and ECG measurements)
             deviating from normal and of clinical relevance

          2. Evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its
             excipients) as judged clinically relevant by the investigator

          8. Intake of drugs with a long half-life (24 hours) within at least 1 month or less than
             10 half-lives of the respective drug prior to randomisation

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to randomisation

         10. Participation in another trial with an investigational drug within 2 months prior to
             randomisation

         11. Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)

         12. Inability to refrain from smoking on trial days as judged by the investigator

         13. Alcohol abuse (more than 30 g alcohol a day)

         14. Drug abuse

         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during
             the trial)

         16. Excessive physical activities within 1 week prior to randomisation or during the trial

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of the study centre
Clinical trial NCT00463840 (phase 1/phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: oxaliplatin, 5fu, folfox 6
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O
Reason stopped: 
    due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically documented pancreatic adenocarcinoma deemed unresectable due to local
             involvement of vessels or organs

          -  Patients with a clear clinical diagnosis of localized pancreatic cancer deemed
             unresectable, who have undergone at least 2 biopsies which were not diagnostic of
             adenocarcinoma, may be entered at the discretion of the principal investigator.

          -  No prior chemotherapy or abdominal radiation therapy.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Clinically measurable or evaluable disease.

          -  Life expectancy of at least 12 weeks.

          -  Adequate bone marrow reserve, granulocyte count >= 1500/uL, platelet count >=
             100,000/uL, hemoglobin >= 9 g/dL.

          -  Adequate renal function with creatinine =< 1.5 times upper limit of normal (ULN)

          -  Adequate biliary function with bilirubin < 3.0 g/dL (including patients who have been
             bypassed or treated with percutaneous drainage), serum glutamic pyruvic transaminase
             (SGPT) (alanine transaminase) =< 2.5

          -  Age > 18 years

          -  Signed informed consent.

          -  No known allergy to one of the study drugs

          -  For female patient of childbearing potential, neither pregnant nor breastfeeding, and
             under active contraception

          -  No prior malignancy within last 5 years

          -  No central nervous system metastases

          -  No peripheral neuropathy > grade2

          -  No other serious concomitant illness

        Exclusion Criteria:

          -  Active infection or uncontrolled infection

          -  Presence of metastatic disease.

          -  Inadequate organ function as discussed above.

          -  Pregnancy

          -  Serious concomitant systemic disorder.

          -  Use of any investigational agent within a month of treatment
Clinical trial NCT00705016 (phase 1/phase 2, status: completed)
Conditions: squamous cell cancer
ICD codes: C96.20, C96.29, D47.09
Drugs: cilengitide 2000 mg once weekly, cilengitide 2000 mg twice weekly, cetuximab, 5-fluorouracil (5-fu), cisplatin
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O, CN1N=NC2=C(N=CN2C1=O)C(N)=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, FC1=CNC(=O)NC1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of SCCHN

          -  At least one measurable lesion either by computerized tomography (CT) scan or magnetic
             resonance imaging (MRI)

          -  Karnofsky performance status (KPS) of greater than or equal to 70 or eastern
             cooperative oncology group performance status (ECOG PS) of 0-1 at trial entry

        Exclusion Criteria:

          -  Prior systemic chemotherapy, except if given as part of a multimodal treatment for
             locally advanced disease, which was completed more than 6 months prior to trial entry

          -  Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before trial
             entry

          -  Nasopharyngeal Carcinoma

          -  Documented or symptomatic brain or leptomeningeal metastasis

          -  Previous treatment with epidermal growth factor receptor (EGFR) targeting therapy or
             signal transduction inhibitors
Clinical trial NCT00479232 (phase 1, status: completed)
Conditions: leukemia, myelocytic, acute myelodysplastic syndromes, myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: vorinostat, decitabine
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is at least 18 years old with refractory/relapsed AML

               -  If untreated AML, patient is older than 60 years old and not a candidate for
                  standard chemotherapy

          -  Patient is at least 4 weeks from prior treatment and has recovered from all prior
             treatment side effects

          -  Patient has no known liver or kidney problems

          -  Patient knows of no reason they can not receive transfusions of blood clotting cells
             (platelets)

          -  Patient is able to swallow capsules

          -  Patients both male and female are willing to practice birth control during the study

        Exclusion Criteria:

          -  Patient has received prior treatment with valproic acid, decitabine or azacitidine

          -  Being is less than 18 years of age or if patient has untreated AML is below 60 years
             of age

          -  Patient is a women who is pregnant or breastfeeding. Patient has an active infection
             that requires antibiotics

          -  Patient has uncontrolled illness including but not limited to the following: heart
             problems (congestive heart failure, unstable angina pectoris, cardiac arrhythmia),
             inflammation of the pancreas; a mental or social condition that may interfere with
             patient following study procedures

          -  Patient has known human immunodeficiency virus (HIV) infection or HIV-related
             malignancy. Patient has a known history of hepatitis B or C infection

          -  Patient currently has another active cancer other than certain types of skin cancer

          -  Patient is heterosexual and able to have a child and is unwilling to practice birth
             control during the study
Clinical trial NCT01179295 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bay86-9766, bay86-9766, bay86-9766, bay86-9766
SMILES: [H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1, [H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1, [H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1, [H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese patients, who are at least 18 years of age at the first screening
             examination/ visit, with advanced or refractory solid tumors not amenable to standard
             therapy.

          -  Histological or cytological documentation of non-hematologic, malignant solid tumor,
             excluding primary brain or spinal tumors, with no current involvement in the central
             nervous system (CNS)

          -  At least one measurable lesion or evaluable disease according to response evaluation
             criteria in solid tumors (RECIST) version 1.1

          -  Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Use of any anti-cancer therapy including chemotherapy, investigational agents or
             devices and immunotherapy within 4 weeks of the first dose of study medication

          -  Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
             pressure > 90 mmHg, despite optimal medical management

          -  Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C

          -  Inadequate bone marrow, liver and renal function

          -  Inability to swallow oral medications or any condition that could affect the
             absorption of orally administered drugs

          -  Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and
             CYP2C19 inhibitors/ inducers
Clinical trial NCT01484561 (phase 1, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550 or placebo, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient must meet the American College of Rheumatology (ACR) classification
             criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the
             seven criteria.

          -  The patient must have active disease at both Screening and predose on Day 1 of Period
             1.

          -  Patient must have had an inadequate response to at least one disease-modifying
             antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or
             intolerance.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Serious medical conditions that would make treatment with CP-690,550 potentially
             unsafe.

          -  A patient who has a history of asthma, multiple allergies or severe allergy (eg,
             anaphylaxis) to any substance. In particular, a history of allergy to iodine,
             povidone-iodine, iohexol or other iodinated contrast media.
Clinical trial NCT00943293 (phase 1, status: terminated)
Conditions: preleukemia, myeloproliferative disorders, lymphoma, myeloma, graft versus host disease
ICD codes: D47.1, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00, D89.810, D89.811, D89.813, D89.812
Drugs: fludarabine, melphalan, campath
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reason stopped: 
    poor accrual; did not enter phase 2
  
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory acute myelogenous or lymphoid leukemia.

          -  Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.

          -  Chronic myelogenous leukemia in accelerated phase or blast-crisis.

          -  Chronic myelogenous leukemia in second or subsequent chronic phase

          -  Recurrent or refractory malignant lymphoma or Hodgkin's disease

          -  Multiple myeloma at high risk for disease recurrence.

          -  Chronic lymphocytic leukemia, relapsed or with poor prognostic features.

          -  Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic
             features.

        Exclusion Criteria:

          -  Clinical progression.

          -  Contra-indications for vaccination.
Clinical trial NCT01084863 (phase 1/phase 2, status: active, not recruiting)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ct-p6, herceptin, paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Are females

          -  Have a Her 2 over-expression

          -  Have ECOG 0 or 1

        Exclusion Criteria:

          -  Current clinical or radiographic evidence CNS metastases

          -  Current Known infection

          -  Pregnant or nursing mother
Clinical trial NCT01887106 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: glpg1205 single ascending doses, oral suspension, placebo single ascending doses, oral suspension, glpg1205, multiple ascending doses, oral suspension, placebo, multiple ascending doses, oral suspension
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male, age 18-50 years

          -  BMI between 18-30 kg/m2

        Exclusion Criteria:

          -  Any condition that might interfere with the procedures or tests in this study

          -  Drug or alcohol abuse

          -  Smoking
Clinical trial NCT01251640 (phase 1/phase 2, status: completed)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: bay86-9766+gemcitabine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients ≥18 years of age

          -  Histological or cytologically confirmed locally advanced, inoperable or metastatic
             pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery

          -  Patients must have at least one uni-dimensional measurable lesion by CT or MRI
             according to RECIST, Version 1.1

          -  Resolution of all acute toxic effects of any prior local treatment to Common
             Terminology Criteria for Adverse Events (CTCAE) Grade </= 1

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) </= 2

          -  Patient has cardiac function, within normal range, as measured by an echocardiogram

        Exclusion Criteria:

          -  Known history of, or symptomatic metastatic brain or meningeal tumors

          -  History of cardiac disease

          -  Active clinically serious infections

          -  Clinically significant (ie. symptomatic) peripheral vascular disease

          -  Pregnant or lactating women; women of childbearing potential not employing adequate
             contraception

          -  Use of strong inhibitors or inducers of CYP3A4

          -  Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic
             cancer, or other malignancy

          -  Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers
             to radiation therapy in adjuvant intention if given within 6 months from start of
             study treatment

          -  Thrombotic or embolic events such within 6 months prior to start of study treatment
Clinical trial NCT00101907 (phase 1, status: terminated)
Conditions: lung cancer, pancreatic cancer, esophageal cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C25.3, K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: amg 706, gemcitabine, cisplatin
SMILES: CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    study terminated per recommendation of data review team
  
Eligibility criteria:

        For complete inclusion and exclusion, please refer to the investigator.

        Inclusion Criteria:

          -  Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved
             informed consent form

          -  Subjects with advanced cancer in whom the gemcitabine and cisplatin chemotherapy
             regimen is clinically indicated

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematological function

          -  Adequate renal function

          -  Adequate hepatic function

          -  Life expectancy of greater than or equal to 3 months as documented by the investigator

        Exclusion Criteria:

          -  More than 1 prior chemotherapy regimen

          -  History of venous thrombosis

          -  Myocardial infarction, cerebrovascular accident, transient ischemic attack,
             percutaneous transluminal coronary angioplasty/stent, or unstable angina within 1 year
             before study enrollment

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan

          -  Average systolic blood pressure of greater than 145 mm Hg or average diastolic blood
             pressure of greater than 85 mm Hg

          -  Radiotherapy within 28 days of study enrollment or within 14 days of study enrollment
             for peripheral lesions

          -  Prior AMG 706, panitumumab, or another anti-EGFr monoclonal antibody (mAb) (e.g.,
             cetuximab [Erbitux®] or EMD 72000)

          -  Systemic chemotherapy within 28 days before study enrollment

          -  Major surgery within 28 days or minor surgery within 14 days of study enrollment

          -  Central nervous system metastases (Exception: subjects with treated asymptomatic
             central nervous system metastases, those who have been clinically stable in the
             judgment of the investigator and off steroids for at least 30 days before the study
             enrollment are eligible)
Clinical trial NCT01261767 (phase 1, status: terminated)
Conditions: inflammation, psoriasis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: anti-il-20, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    trial discontinued due to apparent lack of response in psoriasis measures. no safety concerns
    were present
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with moderate to severe stable chronic plaque psoriasis for at least 6
             months, with or without psoriatic arthritis

          -  Affected body surface area (BSA) greater than or equal to 15%

          -  Physician's Global Assessment (PGA) score of 3 or more

          -  Female subjects of non-childbearing potential or postmenopausal for at least 1 year.
             Male subjects must agree to use effective method of birth control

          -  Body Mass Index (BMI) less than or equal to 38.0 kg/m2

        Exclusion Criteria:

          -  Concomitant anti-psoriatic treatment

          -  Infectious disease requiring systemic anti-infectious treatment within the 2 weeks
             prior to administration of trial drug

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Hepatitis B and/or C (determined by test)

          -  Live virus or bacteria vaccines within the last month before drug administration

          -  Known active herpes/herpes zoster/cold sores

          -  Kidney insufficiency

          -  Liver insufficiency

          -  Lymphoproliferative disease

          -  History or signs of malignancy within the last 5 years